ArticleLeukemia & lymphoma2016

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Lukas D Wartman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.